Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-14 8:45 pm Unchanged | 2024-08-12 | 13D | Savara Inc. SVRA | Growth Equity Opportunities 17 LLC | 24,471,264 14.900% | 0 (Unchanged) | Filing History |
| 2023-07-26 4:57 pm Purchase | 2023-07-17 | 13D | Savara Inc. SVRA | Growth Equity Opportunities 17 LLC | 24,471,264 18.100% | 333,333 (+1.38%) | Filing History |
| 2023-05-02 5:26 pm Sale | 2023-04-18 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 0 0.000% | -2,488,587 (Position Closed) | Filing History |
| 2023-02-03 5:27 pm Sale | 2023-01-27 | 13D | Geron Corporation GERN | Growth Equity Opportunities 17 LLC | 0 0.000% | -20,192,307 (Position Closed) | Filing History |
| 2023-01-27 4:58 pm Sale | 2023-01-20 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 2,488,587 7.500% | -504,371 (-16.85%) | Filing History |
| 2022-08-12 5:15 pm Sale | 2022-07-22 | 13D | VistaGen Therapeutics, Inc. VTGN | Growth Equity Opportunities 17 LLC | 0 0.000% | -543,420 (Position Closed) | Filing History |
| 2021-04-29 10:17 am Purchase | 2021-03-26 | 13D | VistaGen Therapeutics, Inc. VTGN | Growth Equity Opportunities 17 LLC | 543,420 8.600% | 231,420 (+74.17%) | Filing History |
| 2021-03-25 5:10 pm Purchase | 2021-03-15 | 13D | Savara Inc. SVRA | Growth Equity Opportunities 17 LLC | 24,137,931 24.200% | 24,137,931 (New Position) | Filing History |
| 2021-03-15 2:52 pm Purchase | 2021-03-03 | 13D | Satsuma Pharmaceuticals, Inc. STSA | Growth Equity Opportunities 17 LLC | 2,992,958 9.500% | 2,992,958 (New Position) | Filing History |
| 2021-01-04 06:00 am Purchase | 2020-12-22 | 13D | VistaGen Therapeutics, Inc. VTGN | Growth Equity Opportunities 17 LLC | 312,000 6.800% | 312,000 (New Position) | Filing History |
| 2020-06-04 2:58 pm Purchase | 2020-05-27 | 13D | Geron Corporation GERN | Growth Equity Opportunities 17 LLC | 20,192,307 9.600% | 20,192,307 (New Position) | Filing History |